ELACESTRANT
HELP Trial
Phase 2 small_molecule active
Quick answer
ELACESTRANT for Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III) is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active